Recruiting Myelodysplastic Syndromes Studies in Los Angeles
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed hig...
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)...
About Myelodysplastic Syndromes Clinical Trials in Los Angeles
Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature properly. MDS can progress to acute myeloid leukemia. Treatments include growth factors, chemotherapy, and stem cell transplant.
There are currently 2 myelodysplastic syndromes clinical trials recruiting participants in Los Angeles, CALIFORNIA. These studies are seeking a combined 176 participants. Research is being sponsored by Akeso, Rigel Pharmaceuticals. Clinical trial participation is free and participants receive study-related medical care at no cost.
Myelodysplastic Syndromes Clinical Trials in Los Angeles — FAQ
Are there myelodysplastic syndromes clinical trials in Los Angeles?
Yes, there are 2 myelodysplastic syndromes clinical trials currently recruiting in Los Angeles, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Los Angeles?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you about next steps.
Are clinical trials in Los Angeles free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Los Angeles studies also compensate for your time and travel.
What myelodysplastic syndromes treatments are being tested?
The 2 active trials in Los Angeles are testing new therapies including novel drugs, biologics, and treatment approaches for myelodysplastic syndromes.
Data updated March 2, 2026 from ClinicalTrials.gov